

Hong Kong Exchanges and Clearing Limited, The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) and Hong Kong Securities Clearing Company Limited (“**HKSCC**”) take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Unless otherwise defined herein, capitalized terms used in this announcement shall have the same meanings as those defined in the prospectus dated December 18, 2024 (the “**Prospectus**”) issued by Xunfei Healthcare Technology Co., Ltd. (訊飛醫療科技股份有限公司) (the “**Company**”).

This announcement is made pursuant to section 9(2) of the Securities and Futures (Price Stabilizing) Rules (Chapter 571W of the Laws of Hong Kong). This announcement is for information purposes only and does not constitute an offer or an invitation to induce an offer by any person to acquire, purchase or subscribe for securities. This announcement is not a prospectus. Potential investors should read the Prospectus for detailed information about the Global Offering described below before deciding whether or not to invest in the Offer Shares. Any investment decision in relation to the Offer Shares should be taken solely in reliance on the information provided in the Prospectus.

This announcement does not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of Offer Shares in any jurisdiction in which such offer, solicitation or sales would be unlawful. This announcement is not for release, publication, distribution, directly or indirectly, in or into the United States (including its territories and possessions, any state of the United States and the District of Columbia) or any other jurisdiction where such release, publication or distribution is prohibited by law. This announcement does not, and is not intended to, constitute or form a part of any offer to sell or solicitation to purchase or subscribe for any securities in the United States or in any other jurisdiction. The Offer Shares have not been, and will not be, registered under the U.S. Securities Act of 1933, as amended from time to time (the “**U.S. Securities Act**”) or securities law of any state or other jurisdiction of the United States and may not be offered, sold, pledged or otherwise transferred within the United States or to, or for the account or benefit of U.S. persons (as defined in Regulation S under the U.S. Securities Act (the “**Regulation S**”), except pursuant to an available exemption from, or in a transaction not subject to, the registration requirements of the U.S. Securities Act and in compliance with any applicable state securities laws. There will be no public offer of the Offer Shares in the United States. The Offer Shares are being offered and sold solely outside the United States in offshore transactions in reliance on Regulation S under the U.S. Securities Act.

Xunfei Healthcare Technology Co., Ltd.
訊飛醫療科技股份有限公司

(A joint stock company incorporated in the People’s Republic of China with limited liability)
(Stock Code: 2506)

**END OF STABILIZATION PERIOD, NO STABILIZATION ACTIONS
AND LAPSE OF OVER-ALLOTMENT OPTION**

END OF STABILIZATION PERIOD

Pursuant to section 9(2) of the Securities and Futures (Price Stabilizing) Rules (Chapter 571W of the Laws of Hong Kong), the Company announces that the stabilization period in connection with the Global Offering ended on Wednesday, January 22, 2025, being the 30th day after the last day for lodging applications under the Hong Kong Public Offering.

NO STABILIZING ACTIONS AND LAPSE OF THE OVER-ALLOTMENT OPTION

Reference is made to the announcement of the Company dated December 27, 2024. The Overall Coordinators confirmed that there had been no over-allocation of the H Shares in the International Offering. No stabilizing action was taken by the Stabilizing Manager (or any person acting for it) during the stabilization period. Therefore, the Over-allotment Option had not been exercised by the Overall Coordinators (on behalf of the International Underwriters) during the stabilization period and lapsed on Wednesday, January 22, 2025. Accordingly, no H Shares were issued by the Company under the Over-allotment Option.

PUBLIC FLOAT

The Company has applied to the Stock Exchange, and the Stock Exchange has granted the Company a waiver from strict compliance with the minimum public float requirement under Rule 8.08(1)(a) of the Listing Rules to reduce the minimum public float of the Company to the higher of 15.67% of the total number of issued Shares (assuming the Over-allotment Option is not exercised) or such percentage of H Shares to be held by the public after the exercise of the Over-allotment Option (the “**Public Float Waiver**”).

Immediately after the end of the stabilization period, the number of Shares held in public hands represents approximately 15.67% of the total issued share capital of the Company, which satisfies the minimum public float requirement as prescribed in the Public Float Waiver.

By order of the Board
Xunfei Healthcare Technology Co., Ltd.
Dr. Tao Xiaodong
Executive Director

Hong Kong, January 22, 2025

As of the date this announcement, the board of directors of the Company comprises: (i) Dr. Tao Xiaodong as executive director; (ii) Dr. Liu Qingfeng, Mr. Zhao Zhiwei and Mr. Duan Dawei as non-executive directors; and (iii) Prof. Wang Yang, Prof. Zhao Huifang and Mr. Tan Ching as independent non-executive directors.